Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 16Carboplatin 10Paclitaxel 8Nivolumab 7Bevacizumab 6Gemcitabine 4Fulvestrant 4Cisplatin 4olaparib 3lenvatinib 3abemaciclib 3PM 01183 3Oxaliplatin 3Leucovorin 3Letrozole 3Docetaxel 3AZD5305 3tisotumab vedotin 2spartalizumab 2sarilumab 2sargramostim 2sacituzumab govitecan 2ribociclib 2palbociclib 2epacadostat 2enzalutamide 2dostarlimab 2cemiplimab 2anlotinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Endometrial Neoplasms × E-7386 × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡